Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

response

  • Open Access
    First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease
    MOTOKAZU SATO, QINGHONG HAN, CHIHIRO HOZUMI, HIDEO KUJIRAOKA, KOHEI MIZUTA, SEI MORINAGA, BYUNG MO KANG, NORITOSHI KOBAYASHI, YASUSHI ICHIKAWA, ATSUSHI NAKAJIMA and ROBERT M. HOFFMAN
    Anticancer Research September 2024, 44 (9) 3885-3889; DOI: https://doi.org/10.21873/anticanres.17215
  • You have access
    Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification
    YE MA, XIANXIAN LIANG, LI LIU, DAZHI GAO, TAO YANG, ROBERT M. HOFFMAN and JIAN XU
    Anticancer Research November 2021, 41 (11) 5507-5515; DOI: https://doi.org/10.21873/anticanres.15364
  • You have access
    Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma
    TETSUYA YUMIOKA, MASASHI HONDA, RYUTARO SHIMIZU, SHOGO TERAOKA, NORIYA YAMAGUCHI, BUNYA KAWAMOTO, HIDETO IWAMOTO, SHUICHI MORIZANE, KATSUYA HIKITA and ATSUSHI TAKENAKA
    Anticancer Research November 2021, 41 (11) 5767-5773; DOI: https://doi.org/10.21873/anticanres.15393
  • Open Access
    Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase
    QINGHONG HAN and ROBERT M. HOFFMAN
    Anticancer Research April 2021, 41 (4) 1921-1926; DOI: https://doi.org/10.21873/anticanres.14958
  • You have access
    Multidisciplinary Therapy for Locally Advanced Oesophageal Cancer With Special Reference to Surgical Conversion and Salvage
    MAKOTO SOHDA, TATSUYA MIYAZAKI, MAKOTO SAKAI, YUJI KUMAKURA, HIROAKI HONJYO, KEIGO HARA, NARITAKA TANAKA, TAKEHIKO YOKOBORI and KEN SHIRABE
    Anticancer Research June 2019, 39 (6) 3167-3175; DOI: https://doi.org/10.21873/anticanres.13454
  • You have access
    Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer
    DIRK RADES, ANNIKA PANZNER, STEFAN JANSSEN, JUERGEN DUNST, THEO VENINGA, NIELS H. HOLLÄNDER and STEVEN E. SCHILD
    Anticancer Research December 2018, 38 (12) 6897-6903; DOI: https://doi.org/10.21873/anticanres.13066
  • You have access
    Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
    ANDREA SBRANA, ELISA BIASCO, FEDERICO PAOLIERI, ERICA PALESANDRO, CLAUDIA CASERTA, ROBERTO IACOVELLI, BEATRICE DETTI, DANIELE SANTINI, ALESSANDRA MOSCA, FRANCO MORELLI, GIUSEPPE FORNARINI, UGO DE GIORGI, CRISTINA MASINI and LUCA GALLI
    Anticancer Research August 2018, 38 (8) 4913-4918; DOI: https://doi.org/10.21873/anticanres.12807
  • You have access
    Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
    ALEXANDR POPRACH, ONDREJ FIALA, RENATA CHLOUPKOVA, BOHUSLAV MELICHAR, RADEK LAKOMY, KATARINA PETRAKOVA, MILADA ZEMANOVA, KATERINA KOPECKOVA, ONDREJ SLABY, HANA STUDENTOVA, JINDRICH KOPECKÝ, IGOR KISS, JINDRICH FINEK, LADISLAV DUSEK and TOMAS BUCHLER
    Anticancer Research January 2018, 38 (1) 449-456;
  • You have access
    Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults
    SHINSUKE SASADA, MAKOTO KODAIRA, TATSUNORI SHIMOI, AKIHIKO SHIMOMURA, MAYU YUNOKAWA, KAN YONEMORI, CHIKAKO SHIMIZU, YASUHIRO FUJIWARA and KENJI TAMURA
    Anticancer Research May 2016, 36 (5) 2429-2432;
  • You have access
    The Role of Interim 18F-FDG PET/CT in Predicting Early Response to Neoadjuvant Chemotherapy in Breast Cancer
    KISOO PAHK, SEUNGHONG RHEE, JAEHYUK CHO, MINHEE SEO, SINAE LEE, TAEGYU PARK, SOYEON PARK, EUNSUB LEE, KYUNG HWA PARK, CHULHAN KIM, JAE SEON EO, SUNGEUN KIM and JAE GOL CHOE
    Anticancer Research August 2014, 34 (8) 4447-4455;

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire